Clinical trial · Observational
Study of Outcomes of Radiofrequency Ablation of Lung Tumors
A Prospective Study of Outcomes of Radiofrequency Ablation of Lung Tumors
NCT00280189CI-TRIAL-00108172suspendedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess short and long term outcomes after radiofrequency ablation (RFA) of pulmonary malignancies in patients who are not candidates for surgical resection. This study will evaluate the efficacy of RFA for the treatment of lung tumors by assessing its impact on local tumor control, progression free survival, overall survival, dyspnea score and quality of life (QOL).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Pulmonary Metastases | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Assessment of pain | Behavioral | — | UNRESOLVED |
| Quality of life assessment | Behavioral | — | UNRESOLVED |
| Radiofrequency ablation of pulmonary malignancies | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Assess overall survival, progression-free survival and clinical response after RFA
- timeFrame
- Until disease progression or death
Secondary outcomes (2)
- measure
- To characterize QOL before and after RFA treatment
- timeFrame
- Every 3 months for 1 year then annually
- measure
- To assess procedure related outcomes after RFA of lung tumors, in particular, measuring length of stay, morbidity and mortality and requirements for chest tube drainage
- timeFrame
- Within 30 days of RFA procedure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Have stage I or II primary lung cancer and who are felt not to be candidates for resection based upon co-morbid disease or who refuse lung resection. * Have metastatic tumors to the lung, and who meet criteria for metastasectomy but who are felt not to be candidates for resection of all metastases. All metastases should be treatable by RFA alone or in combination with resection. * Have positive tissue diagnosis by previous resection (less than 6 months) or by radiologic biopsy. * Have clinically suspicious disease defined as a new lesion on chest CT or a suspicious PET scan. * Have RF ablation target lesions of 4 centimeters or less in diameter. Exclusion Criteria: * If the lesion is centrally located, less than 3 centimeters from the hilum. * If the target lesion is greater than 4 centimeters in diameter. * If the lesion is metastatic and the primary site is not controlled. * If extra-thoracic metastatic disease is present. * If there are more than 3 tumors in one lung. * If there are greater than 6 metastatic tumors in total (bilateral). * If it is felt that all metastases cannot be treated by RFA alone or in combination with resection. * If the patient is pregnant or nursing at the time of the procedure. * If the patient has malignant pleural effusion. * If the patient is unwilling or unable to provide consent for the procedure. * If the patient is less than 18 years of age (the short form \[SF\]-36 is not designed for patients less than 18 years of age).
References
Publications (0)
Data not yet available
No reference posted for this study.